Last reviewed · How we verify

Glycopyrronium bromide 12.5ug — Competitive Intelligence Brief

Glycopyrronium bromide 12.5ug (Glycopyrronium bromide 12.5ug) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 2 Small molecule Live · refreshed every 30 min

Target snapshot

Glycopyrronium bromide 12.5ug (Glycopyrronium bromide 12.5ug) — Novartis Pharmaceuticals.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Glycopyrronium bromide 12.5ug TARGET Glycopyrronium bromide 12.5ug Novartis Pharmaceuticals phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glycopyrronium bromide 12.5ug — Competitive Intelligence Brief. https://druglandscape.com/ci/glycopyrronium-bromide-12-5ug. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: